113 related articles for article (PubMed ID: 21406033)
1. The evaluation of inhibitive effectiveness of the tumour necrosis factor-α converting enzyme selective inhibitors by HPLC.
Zhao Y; Yu J; Gu J; Huang W
J Enzyme Inhib Med Chem; 2011 Apr; 26(2):181-7. PubMed ID: 21406033
[TBL] [Abstract][Full Text] [Related]
2. Definition of peptide inhibitors from a synthetic peptide library by targeting gelatinase B/matrix metalloproteinase-9 (MMP-9) and TNF-α converting enzyme (TACE/ADAM-17).
Qiu Z; Yan M; Li Q; Liu D; Van den Steen PE; Wang M; Opdenakker G; Hu J
J Enzyme Inhib Med Chem; 2012 Aug; 27(4):533-40. PubMed ID: 21827363
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket.
Huang A; Joseph-McCarthy D; Lovering F; Sun L; Wang W; Xu W; Zhu Y; Cui J; Zhang Y; Levin JI
Bioorg Med Chem; 2007 Sep; 15(18):6170-81. PubMed ID: 17606376
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and activity of tryptophan sulfonamide derivatives as novel non-hydroxamate TNF-alpha converting enzyme (TACE) inhibitors.
Park K; Gopalsamy A; Aplasca A; Ellingboe JW; Xu W; Zhang Y; Levin JI
Bioorg Med Chem; 2009 Jun; 17(11):3857-65. PubMed ID: 19410464
[TBL] [Abstract][Full Text] [Related]
5. Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Duan JJ; Lu Z; Xue CB; He X; Seng JL; Roderick JJ; Wasserman ZR; Liu RQ; Covington MB; Magolda RL; Newton RC; Trzaskos JM; Decicco CP
Bioorg Med Chem Lett; 2003 Jun; 13(12):2035-40. PubMed ID: 12781190
[TBL] [Abstract][Full Text] [Related]
6. Blockade of tumor necrosis factor-alpha-converting enzyme improves experimental small intestinal damage by decreasing matrix metalloproteinase-3 production in rats.
Matsumoto H; Koga H; Iida M; Tarumi K; Fujita M; Haruma K
Scand J Gastroenterol; 2006 Nov; 41(11):1320-9. PubMed ID: 17060126
[TBL] [Abstract][Full Text] [Related]
7. Structure-based rational design of peptide hydroxamic acid inhibitors to target tumor necrosis factor-α converting enzyme as potential therapeutics for hepatitis.
Wu D; Gu Q; Zhao N; Xia F; Li Z
J Drug Target; 2015 Dec; 23(10):936-42. PubMed ID: 26061299
[TBL] [Abstract][Full Text] [Related]
8. Conversion of potent MMP inhibitors into selective TACE inhibitors.
Cherney RJ; King BW; Gilmore JL; Liu RQ; Covington MB; Duan JJ; Decicco CP
Bioorg Med Chem Lett; 2006 Feb; 16(4):1028-31. PubMed ID: 16289878
[TBL] [Abstract][Full Text] [Related]
9. Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Sheppeck JE; Gilmore JL; Tebben A; Xue CB; Liu RQ; Decicco CP; Duan JJ
Bioorg Med Chem Lett; 2007 May; 17(10):2769-74. PubMed ID: 17368021
[TBL] [Abstract][Full Text] [Related]
10. Characterization of Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2, a fluorogenic substrate with increased specificity constants for collagenases and tumor necrosis factor converting enzyme.
Neumann U; Kubota H; Frei K; Ganu V; Leppert D
Anal Biochem; 2004 May; 328(2):166-73. PubMed ID: 15113693
[TBL] [Abstract][Full Text] [Related]
11. Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis.
Zhang Y; Xu J; Levin J; Hegen M; Li G; Robertshaw H; Brennan F; Cummons T; Clarke D; Vansell N; Nickerson-Nutter C; Barone D; Mohler K; Black R; Skotnicki J; Gibbons J; Feldmann M; Frost P; Larsen G; Lin LL
J Pharmacol Exp Ther; 2004 Apr; 309(1):348-55. PubMed ID: 14718605
[TBL] [Abstract][Full Text] [Related]
12. Discovery of selective phosphonamide-based inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Sawa M; Kurokawa K; Inoue Y; Kondo H; Yoshino K
Bioorg Med Chem Lett; 2003 Jun; 13(12):2021-4. PubMed ID: 12781187
[TBL] [Abstract][Full Text] [Related]
13. The P2/P2' sites affect the substrate cleavage of TNF-α converting enzyme (TACE).
Liu S; Liu S; Wang Y; Liao Z
Mol Immunol; 2014 Nov; 62(1):122-8. PubMed ID: 24980871
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Sheppeck JE; Gilmore JL; Yang A; Chen XT; Xue CB; Roderick J; Liu RQ; Covington MB; Decicco CP; Duan JJ
Bioorg Med Chem Lett; 2007 Mar; 17(5):1413-7. PubMed ID: 17188863
[TBL] [Abstract][Full Text] [Related]
15. Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).
Ott GR; Asakawa N; Lu Z; Liu RQ; Covington MB; Vaddi K; Qian M; Newton RC; Christ DD; Traskos JM; Decicco CP; Duan JJ
Bioorg Med Chem Lett; 2008 Jan; 18(2):694-9. PubMed ID: 18061445
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.
Cherney RJ; Duan JJ; Voss ME; Chen L; Wang L; Meyer DT; Wasserman ZR; Hardman KD; Liu RQ; Covington MB; Qian M; Mandlekar S; Christ DD; Trzaskos JM; Newton RC; Magolda RL; Wexler RR; Decicco CP
J Med Chem; 2003 May; 46(10):1811-23. PubMed ID: 12723945
[TBL] [Abstract][Full Text] [Related]
17. 2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors.
Dai C; Li D; Popovici-Muller J; Zhao L; Girijavallabhan VM; Rosner KE; Lavey BJ; Rizvi R; Shankar BB; Wong MK; Guo Z; Orth P; Strickland CO; Sun J; Niu X; Chen S; Kozlowski JA; Lundell DJ; Piwinski JJ; Shih NY; Siddiqui MA
Bioorg Med Chem Lett; 2011 May; 21(10):3172-6. PubMed ID: 21458257
[TBL] [Abstract][Full Text] [Related]
18. The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.
Levin JI; Chen J; Du M; Hogan M; Kincaid S; Nelson FC; Venkatesan AM; Wehr T; Zask A; DiJoseph J; Killar LM; Skala S; Sung A; Sharr M; Roth C; Jin G; Cowling R; Mohler KM; Black RA; March CJ; Skotnicki JS
Bioorg Med Chem Lett; 2001 Aug; 11(16):2189-92. PubMed ID: 11514167
[TBL] [Abstract][Full Text] [Related]
19. Molecular modeling and biological effects of peptidomimetic inhibitors of TACE activity.
Feng WF; Zhao YB; Huang W; Yang YZ
J Enzyme Inhib Med Chem; 2010 Aug; 25(4):459-66. PubMed ID: 19951006
[TBL] [Abstract][Full Text] [Related]
20. Discovery of low nanomolar non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Duan JJ; Chen L; Lu Z; Jiang B; Asakawa N; Sheppeck JE; Liu RQ; Covington MB; Pitts W; Kim SH; Decicco CP
Bioorg Med Chem Lett; 2007 Jan; 17(1):266-71. PubMed ID: 17027261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
